Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK
Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK
NCT ID: NCT04546789 Phase: PHASE1 Status: COMPLETED Enrollment: 24 Completion: 2021-05-16
Conditions
Hepatic Impairment
Interventions
M2951 (BTK inhibitor)
Summary
This study was to investigate the pharmacokinetic (PK) and safety of M2951 (Bruton's tyrosine kinase [BTK] inhibitor) in participants with different degrees of hepatic impairment compared to participants with normal hepatic function.
Primary Outcome
Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of M2951